Your browser is no longer supported. Please, upgrade your browser.
Actinium Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.59 Insider Own1.55% Shs Outstand15.43M Perf Week-8.51%
Market Cap109.62M Forward P/E- EPS next Y-1.42 Insider Trans0.00% Shs Float13.38M Perf Month-0.49%
Income-20.40M PEG- EPS next Q-0.37 Inst Own29.00% Short Float5.24% Perf Quarter-26.46%
Sales- P/S- EPS this Y34.20% Inst Trans31.55% Short Ratio1.29 Perf Half Y-9.74%
Book/sh2.94 P/B2.74 EPS next Y23.70% ROA-64.60% Target Price- Perf Year18.36%
Cash/sh3.54 P/C2.27 EPS next 5Y- ROE-78.00% 52W Range4.71 - 19.47 Perf YTD3.33%
Dividend- P/FCF- EPS past 5Y30.50% ROI- 52W High-58.60% Beta1.10
Dividend %- Quick Ratio10.50 Sales past 5Y- Gross Margin- 52W Low71.13% ATR0.49
Employees25 Current Ratio10.50 Sales Q/Q- Oper. Margin- RSI (14)37.53 Volatility7.01% 6.31%
OptionableYes Debt/Eq0.00 EPS Q/Q70.40% Profit Margin- Rel Volume0.61 Prev Close7.87
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume544.91K Price8.06
Recom1.80 SMA20-8.70% SMA50-11.46% SMA200-20.79% Volume334,917 Change2.41%
Nov-05-20Initiated Alliance Global Partners Buy $25
Dec-06-17Initiated B. Riley FBR, Inc. Buy $2.75
Oct-23-17Resumed ROTH Capital Buy $6
Sep-14-17Initiated Maxim Group Buy $3
Aug-25-16Initiated ROTH Capital Buy $5
Feb-29-16Initiated H.C. Wainwright Buy $8
Oct-15-15Initiated FBR Capital Outperform $12
Oct-01-14Initiated MLV & Co Buy $16
Jul-22-14Initiated Canaccord Genuity Buy $16
Feb-11-21 07:15AM  
Feb-10-21 07:15AM  
Jan-20-21 07:00AM  
Jan-13-21 07:00AM  
Dec-29-20 08:30AM  
Dec-23-20 05:45PM  
Dec-17-20 05:45PM  
Dec-09-20 05:45PM  
Dec-08-20 08:00AM  
Dec-07-20 08:30AM  
Dec-03-20 07:00AM  
Dec-02-20 08:49PM  
Dec-01-20 07:00AM  
Nov-23-20 07:00AM  
Nov-20-20 05:45PM  
Nov-19-20 07:30AM  
Nov-16-20 07:00AM  
Nov-13-20 05:45PM  
Nov-11-20 08:00AM  
Nov-04-20 12:21PM  
Oct-29-20 11:30AM  
Oct-28-20 07:00AM  
Oct-22-20 05:45PM  
Oct-21-20 08:04AM  
Oct-14-20 07:00AM  
Oct-09-20 06:37AM  
Oct-08-20 05:45PM  
Oct-06-20 07:00AM  
Oct-02-20 05:45PM  
Sep-23-20 07:00AM  
Sep-14-20 07:00AM  
Sep-10-20 07:00AM  
Aug-31-20 06:05PM  
Aug-28-20 11:30AM  
Aug-26-20 08:48AM  
Aug-12-20 11:30AM  
Aug-10-20 02:30PM  
Aug-04-20 05:45PM  
Aug-03-20 11:54AM  
Jul-28-20 05:50PM  
Jul-27-20 11:30AM  
Jul-23-20 12:00PM  
Jul-21-20 08:57AM  
Jul-20-20 10:32AM  
Jul-15-20 07:03AM  
Jul-09-20 11:30AM  
Jul-08-20 09:05AM  
Jun-19-20 05:15PM  
Jun-17-20 11:30AM  
Jun-16-20 11:30PM  
Jun-15-20 11:29PM  
Jun-12-20 08:43AM  
Jun-09-20 08:47AM  
Jun-04-20 09:45PM  
Jun-03-20 09:53AM  
Apr-24-20 05:15PM  
Apr-21-20 11:35PM  
Apr-16-20 07:00AM  
Apr-12-20 09:02AM  
Mar-06-20 10:56AM  
Mar-05-20 07:30AM  
Feb-26-20 07:33AM  
Feb-25-20 09:33AM  
Feb-21-20 07:30AM  
Feb-13-20 08:03AM  
Feb-05-20 05:50PM  
Jan-30-20 05:45PM  
Jan-13-20 12:00PM  
Jan-07-20 07:03AM  
Jan-03-20 11:30AM  
Jan-02-20 09:29AM  
Dec-22-19 05:08PM  
Dec-09-19 06:10AM  
Dec-07-19 08:35AM  
Dec-01-19 09:30AM  
Nov-20-19 09:00AM  
Nov-07-19 04:05PM  
Nov-06-19 09:15AM  
Oct-28-19 08:20AM  
Oct-15-19 10:48AM  
Sep-30-19 08:00AM  
Sep-23-19 08:00AM  
Sep-16-19 08:00AM  
Jul-23-19 08:00AM  
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, developing Antibody Radiation-Conjugates (ARCs). The ARCs selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. It also offers Iomab-B (I-131 apamistamab), which is in a phase III study for Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company is also developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.